The turmoil in US equity markets created by the COVID-19 pandemic has resulted in many companies facing depressed stock prices, leaving them vulnerable to unsolicited acquisition proposals or activist activity, which has led to heightened interest in shareholder rights plans (also known as “poison pills”). WilmerHale’s Mergers and Acquisitions practice has prepared a high-level overview of the advantages, disadvantages, prevalence and operation of rights plans.
COVID-19: Revisiting Shareholder Rights Plans
Read more in our Coronavirus (COVID-19) Center.
Joseph B. Conahan
Co-Chair, Mergers and Acquisitions Practice[email protected] +1 617 526 6317
Hal J. Leibowitz
Co-Chair, Mergers and Acquisitions Practice[email protected] +1 617 526 6461